340 related articles for article (PubMed ID: 15937314)
1. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
[TBL] [Abstract][Full Text] [Related]
2. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
[TBL] [Abstract][Full Text] [Related]
3. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
[TBL] [Abstract][Full Text] [Related]
4. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
[TBL] [Abstract][Full Text] [Related]
5. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
6. Improved iodine radiolabels for monoclonal antibody therapy.
Stein R; Govindan SV; Mattes MJ; Chen S; Reed L; Newsome G; McBride BJ; Griffiths GL; Hansen HJ; Goldenberg DM
Cancer Res; 2003 Jan; 63(1):111-8. PubMed ID: 12517786
[TBL] [Abstract][Full Text] [Related]
7. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
[TBL] [Abstract][Full Text] [Related]
9. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
[TBL] [Abstract][Full Text] [Related]
10. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate.
Boerman OC; Kranenborg MH; Oosterwijk E; Griffiths GL; McBride WJ; Oyen WJ; de Weijert M; Oosterwijk-Wakka J; Hansen HJ; Corstens FH
Cancer Res; 1999 Sep; 59(17):4400-5. PubMed ID: 10485489
[TBL] [Abstract][Full Text] [Related]
11. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
[TBL] [Abstract][Full Text] [Related]
12. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
13. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
[TBL] [Abstract][Full Text] [Related]
14. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
Stein R; Goldenberg DM; Thorpe SR; Basu A; Mattes MJ
Cancer Res; 1995 Jul; 55(14):3132-9. PubMed ID: 7606734
[TBL] [Abstract][Full Text] [Related]
15. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
[TBL] [Abstract][Full Text] [Related]
16. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.
Stein R; Govindan SV; Mattes MJ; Shih LB; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3079s-3087s. PubMed ID: 10541347
[TBL] [Abstract][Full Text] [Related]
17. Tumor retention of 186Re-MAG3, 111In-DTPA and 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts.
Steffens MG; Kranenborg MH; Boerman OC; Zegwaart-Hagemeier NE; Debruyne FM; Corstens FH; Oosterwijk E
Cancer Biother Radiopharm; 1998 Apr; 13(2):133-9. PubMed ID: 10850349
[TBL] [Abstract][Full Text] [Related]
18. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.
Gestin JF; Loussouarn A; Bardiès M; Gautherot E; Gruaz-Guyon A; Saï-Maurel C; Barbet J; Curtet C; Chatal JF; Faivre-Chauvet A
J Nucl Med; 2001 Jan; 42(1):146-53. PubMed ID: 11197965
[TBL] [Abstract][Full Text] [Related]
19. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
20. Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results.
Le Doussal JM; Barbet J; Delaage M
Int J Cancer Suppl; 1992; 7():58-62. PubMed ID: 1428406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
